Jump to content

1B-LSD

From Wikipedia, the free encyclopedia
1B-LSD
Clinical data
Other names1-Butyryl-LSD; X-LSD
Routes of
administration		Oral
Drug classSerotonergic psychedelic; Hallucinogen
Legal status
Legal status
Identifiers
  • (6aR,9R)-N,N-diethyl-6-methyl-4-butanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H31N3O2
Molar mass393.531 g·mol−1
3D model (JSmol)
  • CN1[C@](C2=C[C@@H](C(N(CC)CC)=O)C1)([H])CC3=CN(C(CCC)=O)C4=C3C2=CC=C4
  • InChI=1S/C24H31N3O2/c1-5-9-22(28)27-15-16-13-21-19(18-10-8-11-20(27)23(16)18)12-17(14-25(21)4)24(29)26(6-2)7-3/h8,10-12,15,17,21H,5-7,9,13-14H2,1-4H3/t17-,21-/m1/s1
  • Key:SVRFNPSJPIDUBC-DYESRHJHSA-N

1B-LSD, also known as 1-butyryl-LSD, is a psychedelic drug of the lysergamide family and an acylated derivative of lysergic acid diethylamide (LSD) which has been sold as a designer drug.[1]

Use and effects

[edit]

Interactions

[edit]

Pharmacology

[edit]

Pharmacodynamics

[edit]

1B-LSD has been found to produce psychedelic-like effects in rodents similarly to LSD, though with only around 1/7 the potency of LSD itself.[2][3][4]

Chemistry

[edit]

Analogues

[edit]

Related compounds include 1cP-LSD, 1P-LSD, 1V-LSD, ALD-52 (1A-LSD), 1cP-AL-LAD, AL-LAD, ETH-LAD, 1P-ETH-LAD, PRO-LAD, LSM-775, and LSZ, among others.

Society and culture

[edit]
[edit]

Canada

[edit]

1B-LSD is not a controlled substance in Canada as of 2025.[5]

Singapore

[edit]

1B-LSD is illegal in Singapore.[6] Sweden's public health agency suggested classifying 1B-LSD as a hazardous substance, on June 24, 2019.[7]

United States

[edit]

1B-LSD is not an explicitly controlled substance in the United States.[8] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

[edit]

References

[edit]
  1. ↑ Tsochatzis E, Lopes JA, Reniero F, Holland M, Åberg J, Guillou C (February 2020). "Identification of 1-Butyl-Lysergic Acid Diethylamide (1B-LSD) in Seized Blotter Paper Using an Integrated Workflow of Analytical Techniques and Chemo-Informatics". Molecules. 25 (3): 712. doi:10.3390/molecules25030712. PMC 7037844. PMID 32045999.
  2. ↑ Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, et al. (July 2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures" (PDF). Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9. PMID 30617391. S2CID 58615418.
  3. ↑ Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, et al. (August 2019). "Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)". Drug Testing and Analysis. 11 (8): 1122–1133. doi:10.1002/dta.2613. PMC 6899222. PMID 31083768.
  4. ↑ Halberstadt AL, Chatha M, Klein AK, McCorvy JD, Meyer MR, Wagmann L, et al. (August 2020). "Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)" (PDF). Neuropharmacology. 172 107856. doi:10.1016/j.neuropharm.2019.107856. PMC 9191647. PMID 31756337. S2CID 208155327.
  5. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
  6. ↑ "Misuse of Drugs Act - Singapore Statutes Online". sso.agc.gov.sg.
  7. ↑ "Åtta ämnen föreslås klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 24 June 2019. Archived from the original on 18 November 2019. Retrieved 29 May 2020.
  8. ↑ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=1B-LSD&oldid=1367788903"